Metformin at the Interface of Chemistry, Pharmacokinetics, and Clinical Translation: Mechanistic Insights into Efficacy and Adverse Effects
DOI:
https://doi.org/10.54097/an955p74Keywords:
Metformin, Transporter-dependent pharmacokinetics, Mitochondrial complex I inhibition, Gut-liver axis, Precision medicineAbstract
Metformin is a key drug for the treatment of type 2 diabetes. Its efficacy and side effects depend on its chemical properties and how it is transported through transporters in the body. Research has shown that these factors influence metformin's function, individual variability, and potential safety issues. Metformin exerts its effects by inhibiting mitochondrial complex I and activating AMP-activated protein kinase (AMPK) during periods of energy deprivation. Furthermore, it alters glucose processing in the intestine and liver through the PEN2-ATP6AP1 signaling pathway. These effects also influence gut hormones and the composition of the gut microbiota. This process explains metformin's effects on blood glucose, gastrointestinal intolerance, vitamin B12 deficiency, and lactic acidosis. Understanding the underlying mechanisms of these effects opens new avenues for clinical application. Adjusting dose based on transporter differences can improve efficacy. Modifying the gut microbiota can alleviate gastric intolerance. Developing new drugs in this class could provide more effective treatment options. These results suggest that understanding metformin's function could lead to more personalized and effective treatments for type 2 diabetes.
Downloads
References
[1] Peng, A., Gong, C., Xu, Y., Liang, X., Chen, X., Hong, W., & Yan, J. (2023). Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis. Frontiers in Public Health, 11, 1183879.
[2] Reczek, C. R., Chakrabarty, R. P., D’Alessandro, K. B., Sebo, Z. L., Grant, R. A., Gao, P., ... & Chandel, N. S. (2024). Metformin targets mitochondrial complex I to lower blood glucose levels. Science Advances, 10 (51), eads5466.
[3] Liu, L., Patnana, P. K., & Nimmagadda, S. C. (2022). Low-dose metformin and PEN2-dependent lysosomal AMPK activation: benefits outnumber side effects. Signal Transduction and Targeted Therapy, 7 (1), 178.
[4] Sugawara, K., & Ogawa, W. (2022). New mechanism of metformin action mediated by lysosomal presenilin enhancer 2. Journal of Diabetes Investigation, 14 (1), 12.
[5] Yang, C., Chen, H., Huang, X., Zhou, L., & Yuan, X. (2025). GDF15: An emerging disease target and biomarker of metabolic diseases. Journal of Endocrinological Investigation, 1-14.
[6] Rönnpagel, V., Morof, F., Römer, S., Meyer-Tönnies, M. J., & Tzvetkov, M. V. (2025). Substrate-specific inhibition of organic cation transporter 1 revealed using a multi-substrate drug cocktail. Drug Metabolism and Disposition, 100074.
[7] Hatmal, M. M. M., Abuyaman, O., Al-Hatamleh, M. A., Tayyem, H., Olaimat, A. N., Mussa, A., ... & Qawaqzeh, R. (2025). Influence of OCT2 gene variants on metformin efficacy in type 2 diabetes: insights into pharmacogenomics and drug interactions. Journal of Translational Medicine, 23 (1), 884.
[8] Borra, S. S., Jane, N. R., Palaniappan, D., Subramanian, R., Patankar, M. A., Krishnamoorthy, S. G., & Parthasarathy, A. K. (2023). Genetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative review. Egyptian Journal of Medical Human Genetics, 24 (1), 13.
[9] Chávez-Arreola, O. I., Lazalde, B., López-López, M., Ortega-Vázquez, A., & Torres-Salazar, Q. L. (2024). Allele frequencies and genotype distribution of three metformin transporter polymorphisms in Mexican population and their application in pharmacogenomics of type 2 diabetes. Frontiers in Pharmacology, 15, 1466394.
[10] Cheng, M., Ren, L., Jia, X., Wang, J., & Cong, B. (2024). Understanding the action mechanisms of metformin in the gastrointestinal tract. Frontiers in Pharmacology, 15, 1347047.
[11] Fatima, M., Sadeeqa, S., & Nazir, S. U. R. (2018). Metformin and its gastrointestinal problems: A review. Biomed Res, 29 (11), 2285-2289.
[12] Zhao, B., Li, Z., He, Z., Zhou, X., Yu, Y., Ren, K., & Yan, P. (2021). Metformin and Lactic Acidosis in Diabetic Patients. Journal of Endocrinology Research, 3 (1).
[13] Xiao, G., Tsukada, H., Chen, Y. L., Shi, L., Hopkins, S. C., & Galluppi, G. R. (2024). Evaluation of OCT2‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia. Pharmacology research & perspectives, 12 (2), e1191.
[14] Nabrdalik, K., Drożdż, K., Kwiendacz, H., Skonieczna-Żydecka, K., Łoniewski, I., Kaczmarczyk, M., ... & Gumprecht, J. (2023). Clinical trial: probiotics in metformin intolerant patients with type 2 diabetes (ProGasMet). Biomedicine & Pharmacotherapy, 168, 115650.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
